BioCryst Pharmaceuticals | BCRX - Interest Expense On Debt


BioCryst Pharmaceuticals reported $21.71M in Interest Expense on Debt for its fiscal quarter ending in June of 2026.





Interest Expense On Debt Change Date
Alnylam Pharmaceuticals USD 82.05M 12.76M Jun/2026
BioCryst Pharmaceuticals USD 21.71M 7.58M Jun/2026
Chugai Pharma JPY 95M 260M Dec/2025
Daiichi Sankyo JPY 3.57B 1.4B Mar/2026
DBV Technologies USD 461K 323.71K Mar/2025
Enanta Pharmaceuticals USD 1.96M 620K Dec/2024
Gilead Sciences USD 247M 7M Jun/2026
GlaxoSmithKline GBP 121M 46M Jun/2026
Glaxosmithkline GBP 192.73M 14.79M Mar/2026
Incyte USD 582K 13K Jun/2026
Ionis Pharmaceuticals USD 18M 1000K Jun/2026
Karyopharm Therapeutics USD 12.55M 66K Mar/2026
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Novavax USD 5.82M 342K Dec/2025
PTC Therapeutics USD 3.25B 381.37M Jun/2026
Regeneron Pharmaceuticals USD 11M 1.9M Jun/2026
Roche Holding CHF 304M 7.5M Jun/2025
Sarepta Therapeutics USD 21.51M 205K Jun/2026
Ultragenyx Pharmaceutical USD 22M 1000K Jun/2026
Vertex Pharmaceuticals USD 3.3M 0 Dec/2025